Multiple Myeloma Clinical Trial

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Summary

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy
Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody

Measurable disease defined by at least one of the following:

Serum M-protein >/= 0.5 g/dL by SPEP
Urinary M-protein excretion >/= 200 mg/24 hours by UPEP
Serum immunoglobulin FLC >/= 10 mg/dL (>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
ECOG performance status 0 -1
Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade
Exclusion Criteria:

Active plasma cell leukemia
Amyloidosis
Stem cell transplant with 12 weeks prior to enrollment, or active GVHD
POEMS syndrome
Any active uncontrolled bacterial, fungal, or viral infection
Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment
Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)
Sub-Study A Only: Previous treatment with BCMA bispecific antibody
Sub-Study B Only: Previous treatment with BCMA directed therapy

Study is for people with:

Multiple Myeloma

Phase:

Phase 2

Estimated Enrollment:

105

Study ID:

NCT05090566

Recruitment Status:

Recruiting

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 20 Locations for this study

See Locations Near You

Beverly Hills Cancer Center
Beverly Hills California, 90211, United States
Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center
Coral Gables Florida, 33146, United States
Sylvester Comprehensive Cancer Center- Deerfield Beach
Deerfield Beach Florida, 33442, United States
Sylvester Comprehensive Cancer Center
Miami Florida, 33136, United States
UHealth Tower
Miami Florida, 33136, United States
UChicago Medicine - River East
Chicago Illinois, 60611, United States
University of Chicago Medical Center
Chicago Illinois, 60637, United States
UChicago Medicine at Ingalls - Flossmoor
Flossmoor Illinois, 60422, United States
UChicago Medicine Ingalls Memorial
Harvey Illinois, 60426, United States
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
New Lenox Illinois, 60451, United States
The University of Chicago Medicine Center for Advanced Care Orland Park
Orland Park Illinois, 60462, United States
UChicago Medicine at Ingalls - Tinley Park
Tinley Park Illinois, 60477, United States
University of Iowa Hospitals and Clinics
Iowa City Iowa, 52242, United States
The University of Kansas Cancer Center ,Investigational Drug Services
Fairway Kansas, 66205, United States
The University of Kansas Clinical Research Center
Fairway Kansas, 66205, United States
The University of Kansas Hospital Investigational Drug Services
Kansas City Kansas, 66103, United States
The University of Kansas Hospital
Kansas City Kansas, 66160, United States
The University of Kansas Medical Center Medical Office Building
Kansas City Kansas, 66160, United States
University of Kansas Hospital Cambridge North Tower A
Kansas City Kansas, 66160, United States
The University of Kansas Cancer Center - Indian Creek Campus
Overland Park Kansas, 66211, United States
The University of Kansas Cancer Center
Westwood Kansas, 66205, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Tom Baker Cancer Center
Calgary Alberta, T2N4N, Canada
The Ottawa Hospital - General Campus
Ottawa Ontario, K1H 8, Canada
Princess Margaret Cancer Centre
Toronto Ontario, M5G 2, Canada

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 2

Estimated Enrollment:

105

Study ID:

NCT05090566

Recruitment Status:

Recruiting

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.